Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 2 , Pages 162-171 , June 2010

Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program

  • Michael A. Pfaller

      Affiliations

    • University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
    • Corresponding Author InformationCorresponding author. Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. Tel.: +1-319-356-8615; fax: +1-319-356-4916.
    • ,
  • Daniel J. Diekema

      Affiliations

    • University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
    • ,
  • David L. Gibbs

      Affiliations

    • Giles Scientific, Inc., Santa Barbara, CA 93103, USA
    • ,
  • Vance A. Newell

      Affiliations

    • Giles Scientific, Inc., Santa Barbara, CA 93103, USA
    • ,
  • Richard Barton

      Affiliations

    • General Infirmary, P.H.L.S., Leeds LS1 3EX, UK
    • ,
  • Hu Bijie

      Affiliations

    • Zhong Shan Hospital, Shanghai 200032, China
    • ,
  • Jacques Bille

      Affiliations

    • Institute of Microbiology, CHUV, Lausanne, Switzerland
    • ,
  • Shan-Chwen Chang

      Affiliations

    • National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Maria da Luz Martins

      Affiliations

    • Instituto de Higiene de Medicina Tropical, Lisboa 1349-008, Portugal
    • ,
  • Adriano Duse

      Affiliations

    • WITJ University, Johannesburg, South Africa
    • ,
  • Danuta Dzierzanowska

      Affiliations

    • Children's Memorial Health Institute, Warsaw, Poland
    • ,
  • David Ellis

      Affiliations

    • Womens and Children's Hospital, North Adelaide SA 5006, Australia
    • ,
  • Jorge Finquelievich

      Affiliations

    • Centro de Micologia, Buenos Aires, Argentina
    • ,
  • Ian Gould

      Affiliations

    • Aberdeen Royal Hospital, Aberdeen, Aberdeen City AB25 2, UK
    • ,
  • Deniz Gur

      Affiliations

    • Hacettepe University—Children's Hospital, Ankara, Turkey
    • ,
  • Anwar Hoosen

      Affiliations

    • Ga-Rankuwa Hospital, Medunsa 0204, South Africa
    • ,
  • Kyungwon Lee

      Affiliations

    • Yonsei University College of Medicine, Seoul 120-752, South Korea
    • ,
  • Nada Mallatova

      Affiliations

    • Hospital Ceske Budejovice, Ceske, Czech Republic
    • ,
  • Michele Mallie

      Affiliations

    • Faculte de Pharmacie, 34060 Montpellier, France
    • ,
  • NG Kee Peng

      Affiliations

    • University Malaya, 50603 Kuala Lumpur, Malaysia
    • ,
  • George Petrikos

      Affiliations

    • Laikon General Hospital, Athens 11527, Greece
    • ,
  • Axel Santiago

      Affiliations

    • Universitario de Caracas, Caracas, Venezuela
    • ,
  • Jan Trupl

      Affiliations

    • SYNLAB s.r.o., Bratislava, Slovak Republic
    • ,
  • Ann Marie VanDen Abeele

      Affiliations

    • St. Lucas Campus Heilige Familie, Gent, Belgium
    • ,
  • Jeannette Wadula

      Affiliations

    • Baragwanath Hospital, Johannesburg 2013, South Africa
    • ,
  • Mussaret Zaidi

      Affiliations

    • Hospital General O'Horan, Merida 97000, Mexico
    • ,
  • the Global Antifungal Surveillance Group

Received 5 November 2009 ,Accepted 7 January 2010.

References 

  1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 1997;24:1122–1128
  2. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80:868–871
  3. Almirante B, Rodriquez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 2005;43:1829–1835
  4. Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonkeyder HC, Knudsen JD, Jensen IM, et al. Semi-national surveillance of fungaemia in Denmark, 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 2008;14:487–494
  5. Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J. Antimcirob. Chemother. 2007;60:459–460
  6. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol. 2002;40:3489–3492
  7. Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital. Diagn. Microbiol. Infect. Dis. 2001;39:199–201
  8. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 2008;52:3022–3028
  9. Bilgen H, Ozek E, Korten V, et al. Treatment of systemic neonatal candidiasis with fluconazole. Infection. 1995;23:394
  10. Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-years evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob. Agents Chemother. 1998;42:734–738
  11. Chen YC, Chong SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother. 2003;52:71–77
  12. Cheng MF, Yu KW, Tant RB, Fan YH, Yang YL, Hsieh KS, et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 2004;48:33–37
  13. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 2008;46:1206–1213
  14. Clinical and Laboratory Standards Institute (CLSI) . Method for antifungal disk diffusion testing of yeasts; approved standard, M44-A. Wayne, PA: CLSI; 2004;
  15. Clinical and Laboratory Standards Institute (CLSI) . Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement (M44-S2). Wayne, PA: CLSI; 2007;
  16. Collins DC, Eschenauer GA, Salo SL, Newton DW. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemia. J. Clin. Microbiol. 2007;45:1884–1888
  17. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 2006;43:25–31
  18. Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol. Drug Saf. 2007;16:919–927
  19. Gonzalez GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J. Clin. Microbiol. 2008;46:2902–2905
  20. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Sa MB, Johnson EM, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009;36:55–62
  21. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–2499
  22. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based surveillance program. J. Clin. Microbiol. 2004;42:1519–1527
  23. Hedderwick SA, Wan JY, Bradley SF, Sangeorzan JA, Terpening MS, Kauffman CA. Risk factors for colonization with yeast species in a Veterans Affairs long-term care facility. J. Am. Geriatr. Soc. 1998;46:849–853
  24. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaci AJ, et al. Clinical characteristics of 2019 patients with candidemia: data from the PATH Alliance Registry. Clin. Infect. Dis. 2009;48:1695–1703
  25. Hseuh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb. Drug Resist. 2002;8:311–319
  26. Hseuh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Syr JM, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 2005;49:512–517
  27. Klevay MJ, Horn DL, Neofytos D, Pfaller MA, Diekema DJ. Initial treatment and outcome of Candida glabrata versus C. albicans bloodstream infection. Diagn. Microbiol. Infect. Dis. 2009;64:152–157
  28. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother. 2005;56:532–537
  29. Lee I, Fishman NO, Zauotis TE, Morales KH, Weiner MG, Synnestvedt M, et al. Risk factors for fluconazole-resistant C. glabrata bloodstream infections. Arch. Intern. Med. 2009;169:379–383
  30. Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata, an emerging oral opportunistic pathogen. J. Dent. Res. 2007;86:204–215
  31. Lichtenstein C, Nguyen TH, Schemon P, Hoppe-Tichy T, Weigland MA. Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy. Mycoses. 2008;51(Suppl. 1):35–46
  32. Luzzati R, Amalfitano G, Lazzarini L, Soldori F, Bellino S, Solbiatic M, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 2000;19:602–607
  33. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 2006;44:529–535
  34. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman C. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 2005;41:975–981
  35. Marchetti O, Bille J, Fluckinger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin. Infect. Dis. 2004;38:311–320
  36. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 2000;181:309–316
  37. Morrell M, Fraser VJ, Kollef MJ. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 2005;49:3640–3645
  38. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 1996;100:617–623
  39. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 2003;47:3149–3154
  40. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 2006;44:1740–1743
  41. Pappas PG. The patient with candidemia: treatment choices and algorithms. Curr. Fungal Infect. Rep. 2008;2:112–119
  42. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 2004;38:161–189
  43. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;38:161–189
  44. Parkins MD, Sabuda DM, El Sayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 2007;60:613–618
  45. Pasqualotto AC, Zimerman RA, Alves SH, Aquino VR, Branco D, Wiltgen D, et al. Take control over your fluconazole prescription: the growing important of Candida glabrata as an agent of candidemia in Brazil. Infect. Control. Hosp. Epidemiol. 2008;29:898–899
  46. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. 2007;45:321–346
  47. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 2004;10(Suppl. 1):11–23
  48. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007;20:133–163
  49. Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 2007;1:74–92
  50. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol. 2003;41:2176–2179
  51. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 to 2002. J. Clin. Microbiol. 2004;42:3142–3146
  52. Pfaller MA, Hazen KC, Messer SA, Boyken L, Tendolkar S, Hollis RJ, et al. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 2004;42:3607–3612
  53. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 2005;43:5208–5213
  54. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 2006;19:435–447
  55. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microibol. 2006;44:819–826
  56. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 2007;45:1735–1745
  57. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 2008;46:150–156
  58. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA the Global Antifungal Surveillance Goup. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2009;submitted
  59. Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States, 2001–2007. J. Clin. Microbiol. 2009;47:3185–3190
  60. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis. 2009;65:27–34
  61. Poikonen E, Lyytikainen O, Arttila VJ, Ruutu P. Candidemia in Finland, 1995–1999. Emerg. Infect. Dis. 2003;9:352–356
  62. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 2007;356:2472–2482
  63. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A the French Candidemia Study Group. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect. 2002;8:405–412
  64. Riddell JIV, Kauffman CA. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer. 2008;112:2334–2337
  65. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 2008;14:136–140
  66. Sandven P, Bevanger L, Digranes A, Houklend HH, Mannsaker T, Gaustad P the Norwegian Yeast Study Group. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 2006;44:1977–1981
  67. Sendid B, Cotteau A, Francois N, D'Haveloose A, Standaert A, Camus D, et al. Candidemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect. Dis. 2006;6:80–89
  68. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, et al. Do clinical features allow for accurate predictions of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit. Care Med. 2007;35:1077–1083
  69. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 2006;43:1060–1068
  70. Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 2006;42:244–251
  71. Tan TY, Tan AL, Tee NWS, Ng LSY. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore Hospitals. Ann. Acad. Med. Singapore. 2008;37:835–840
  72. Tortorano AM, Biraghi E, Astofi A, Ossi C, Tejada M, Farina C, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J. Hosp. Infect. 2002;51:297–304
  73. Tortorano AM, Kibbler C, Peman J, Bernhandt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents. 2006;27:359–366
  74. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, the National Nosocomial Infections Surveillance System Hospitals . Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis. 2002;35:622–630
  75. Wilson AG, Micek ST, Ritchie DJ. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin. Ther. 2005;27:1228–1237
  76. Xess I, Jain N, Hasan F, Mandal P, Banerjie U. Epidemiology of candidemia in a tertiary care centre of North India: 5-year study. Infection. 2007;35:256–259
  77. Yang YL, Chang HH, Lo HJ, the TSARY Hospitals . Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med. Mycol. 2006;44:237–242

PII: S0732-8893(10)00006-4

doi: 10.1016/j.diagmicrobio.2010.01.002

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 2 , Pages 162-171 , June 2010

Article Tools